Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues - Wolin, E M; Jarzab, B; Eriksson, B (Drug Des Devel Ther, 2015)
(Sep):